Loading
When two approved drugs are both reasonable next steps and nobody knows which should come first, let the clinic flip a coin and record what happens.
Point-of-care randomisation embedded in the electronic record (as in the TASTE trial in cardiology and the NHS PRINCIPLE platform) can answer sequencing questions about approved drugs with thousands of patients at low cost. Consent is simplified because both options are standard of care; follow-up uses routine data.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence, Weak real-world evidence and registries.
Shares ADC sequencing, Too many combinations to test, Real-world evidence, Weak real-world evidence and registries.
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Payers cover off-label combinations only inside registry-randomised trials, Real-world evidence.
Shares Sequential multiple-assignment randomised trials to find the best order of ADCs, ADC sequencing, HR-positive / HER2-negative breast cancer.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.